(NP (NP (NP (DT A) (NN microtitre) (NN assay) (NN system)) (PP (IN for) (NP (NN glucocorticoid) (NNS receptors))) (: :)) (NP (NP (VBN decreased) (NN receptor) (NN concentration)) (PP (IN in) (NP (JJ myocardial) (NN infarction))) (. .)))
(S (NP-SBJ (NP (DT A) (JJ major) (NN difficulty)) (PP (IN in) (NP (NP (NN determination)) (PP (IN of) (NP (NN glucocorticoid) (NN receptor) (NNS sites)))))) (VP (VBZ is) (NP-PRD (DT the) (ADJP (RB very) (JJ complicated)) (NN assay) (NN procedure))) (. .))
(S (ADVP (RB Therefore)) (, ,) (NP-SBJ-32 (PRP we)) (VP (VBP describe) (NP (NP (DT a) (NN microtitre) (NN assay) (NN system)) (PP (IN for) (NP (NN glucocorticoid) (NNS receptors))) (SBAR (WHNP-33 (WDT which)) (S (NP-SBJ (-NONE- *T*-33)) (VP (VBZ is) (NP-PRD (DT a) (JJ whole-cell) (JJ competitive) (NN binding) (NN radioassay)))))) (S (NP-SBJ (-NONE- *-32)) (VP (VBG using) (NP (NN -LCB-3H-RCB--dexamethasone)) (PP (IN as) (NP (NN radioligand)))))) (. .))
(S (NP-SBJ (NP (DT This) (NN modification)) (PP (IN of) (NP (DT a) (ADJP (RB previously) (VBN described)) (NN protocol)))) (VP-COOD (VP (VP-COOD (VP (VBZ simplifies) (NP (-NONE- *RNR*-34))) (CC and) (VP (VBZ reduces) (NP (-NONE- *RNR*-34)))) (NP-34 (NN laboratory) (NN work))) (CC and) (VP (VBZ allows) (S (NP-SBJ-35 (NN assay) (NN reproducibility)) (VP (TO to) (VP (VB be) (VP (VBN controlled) (NP (-NONE- *-35)) (ADVP (RBR more) (RB reliably)))))))) (. .))
(S (S-ADV (NP-SBJ-37 (-NONE- *-36)) (VP (ADVP (RB Thus)) (VBN enabled) (S (NP-SBJ-38 (-NONE- *-37)) (VP (TO to) (VP (VB perform) (NP (DT the) (NN test)) (PP (IN on) (NP (JJ multiple) (NN blood) (NNS samples))) (PP (IN in) (NP (NN parallel)))))))) (, ,) (NP-SBJ-36 (PRP we)) (VP (VBD investigated) (NP (JJ cardiac) (NN infarction) (NNS patients)) (PP-TMP (IN over) (NP (DT a) (JJ 12-day) (NN period))) (S (NP-SBJ (-NONE- *-38)) (VP (TO to) (VP (VB test) (SBAR (IN if) (S (NP-SBJ-39 (NN glucocorticoid) (NN receptor) (NN binding)) (VP (VBZ is) (VP (VBN altered) (NP (-NONE- *-39)) (PP (IN in) (NP (DT this) (`` ') (JJ stressful) ('' ') (NN disease))))))))))) (. .))
(S-COOD (S (PP-TMP (IN On) (NP (NP (DT the) (JJ first) (NN day)) (PP (IN of) (NP (DT the) (NN disease))))) (, ,) (NP-SBJ-40 (NN glucocorticoid) (NN receptor) (NN capacity)) (VP (VBD was) (ADVP (RB significantly)) (VP (VBN decreased) (NP (-NONE- *-40)) (PP (IN without) (NP (NP (NN alteration)) (PP (IN of) (NP (DT the) (JJ receptor-ligand) (NN affinity)))))))) (, ,) (IN whereas) (S (PP-TMP (IN on) (NP (NNS days) (NP-COOD (NP (CD 4)) (CC and) (NP (CD 12))))) (NP-SBJ (NP (DT the) (NN number)) (PP (IN of) (NP (NN receptor) (NNS sites)))) (VP (VBD was) (ADJP-PRD (JJ normal)) (ADVP (RB again)))) (. .))
(S (NP-SBJ (DT This) (NN result)) (VP (VBZ fits) (ADVP (RB well)) (PP (IN into) (NP (NP (DT the) (JJ general) (NN observation)) (PP (IN of) (NP (NP (JJ stress-induced) (NN down-regulation)) (PP (IN of) (NP (JJ immune) (NNS responses)))))))) (. .))
